Tagged with Biotech,

Switzerland What if the key to treating chronic and age-related diseases has been hidden in plain sight, within the 98 percent of the human genome once written off as “junk”? HAYA Therapeutics is betting on it. In this interview, CEO and Scientific Co-Founder Samir Ounzain reveals how his obsession with the…

Switzerland Patrick Amstutz co-founded Molecular Partners 20 years ago with a vision to revolutionize medicine through protein engineering. Inspired by the potential of DARPins, a novel class of custom-built protein drugs, he has led the company through key milestones—including breakthroughs in ophthalmology, infectious diseases, and oncology. Today, Molecular Partners focuses on…

Switzerland Alentis Therapeutics, under the leadership of its CEO Roberto Iacone, has made significant strides in advancing innovative therapies targeting Claudin-1, a protein critical in inflammation and cancer. The company’s pipeline includes promising antibody-drug conjugates (ADCs), such as ALE.P02, currently in a Phase I/II clinical trial, and ALE.P03, expected to enter…

Switzerland Daniela Marino, CEO and co-founder of CUTISS, leads a pioneering Swiss “tech-bio” company developing personalised skin grafts through advanced tissue engineering. With roots in academic research and over EUR 90 million raised, CUTISS has brought its lead product into Phase III trials, targeting burns and reconstructive surgery. Their unique approach…

Switzerland From its roots as a family-run ophthalmology business to its bold reinvention as a precision oncology biotech, CIS Biopharma is charting a distinctive course through the rapidly evolving life sciences landscape. Leading this transformation, CEO Christoph Schäfer shares the strategic rationale behind the company’s evolution, offering insight into how scientific…

Switzerland Nicolas Durand, CEO of Fondation Campus Biotech Geneva, shares insights into the foundation’s unique role as a catalyst for neuroscience and digital health innovation in Switzerland. In this interview, Durand discusses the foundation’s collaborative model, the importance of building critical mass in a specialised domain, and how Fondation Campus Biotech…

Europe With the proposed Biotech Act, the European Commission (EC) is aiming to boost the EU biotech industry’s competitivity in the face of major rivals like the US and China. Tackling the EU bloc’s regulatory complexity and its barriers to funding is not an easy task, but biotech stakeholders eye the…

Sweden Even though the development of these treatments takes time, there are many capable people continuing to push the field forward. I believe that lecanemab, BioArctic, and others dedicated to this area will keep innovating, learning, and improving—ultimately leading to better outcomes for patients with Alzheimer’s. Lars Lannfelt, co-founder and board…

China Illumina has been swept into the trade conflict between the US and China. After the Trump administration declared a 10 percent tariff on Chinese goods in February, Beijing retaliated by blacklisting the American gene sequencing giant. But beyond the implications for the company, as the trade conflict continues to rage…

LatAm A roundup of some of the biggest stories coming out of Latin American pharma and healthcare, including Mexico’s move to speed up the drug review process; Sanfer’s acquisition of Columbia’s Laboratorio Vitalis; Pfizer’s joint vaccine effort with PAHO and Argentinian drugmaker Sinergium Biotech, and the epilspsy joint venture between SK Biopharmaceuticals…

China A roundup of some of the biggest stories coming out of China’s pharma industry, including the news that AstraZeneca may be seeing the other side of country’s probes; the counter-sanction of US biotech Illumina; Bio X Cell’s new Beijing distribution centre, and the European approval of Shanghai Henlius Biotech’s extensive-stage…

USA Since Christopher Viehbacher took the reins of Biogen in 2022, he has launched a USD 1 billion cost-cutting and priority refocusing plan, made significant deals, and launched the firm’s Alzheimer’s drug Legembi. But snags slowing the uptake of the Eisai-partnered med and the fall in sales of its multiple sclerosis…